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Systemic therapy is the mainstay of treatment of advancedstage non-small cell lung cancer (NSCLC) and is also
integral to therapy for earlier stages of the disease. Combi-
nation chemotherapy regimens confer modest improvement
in overall outcomes for patients with various stages of
NSCLC. The emergence of molecularly targeted agents has
paved the way for individualized treatment approaches for
NSCLC and provides hope that newer classes of drugs can be
developed successfully. This article provides an update on
some novel targeted therapeutic approaches under evaluation
for the treatment of NSCLC.
SUMMARY OF PRESENTATIONS
Histone Deacetylase Inhibitors
Histones are the core proteins in the double helical
structure of DNA. Acetylation of histone proteins, mediated
by histone acetyl transferase, leads to conformational changes
in DNA that favor the transcriptional process.1 On the other
hand, histone deacetylase (HDAC) renders the DNA to a
transcriptionally inactive state. The dynamic equilibrium be-
tween the acetylated and deacetylated states of histone pro-
teins is altered in the milieu of cancer. Therapeutic inhibition
of HDAC results in transcription of several important cell
cycle regulatory proteins and could, therefore, be used for the
treatment of cancer. A number of HDACs have been de-
scribed in the literature, but the class I enzymes are consid-
ered to be the most relevant for the treatment of cancer. In
addition to their effects on the histone proteins, HDAC
inhibitors also affect the acetylation of nonhistone proteins
that play major roles in cancer. Vorinostat, a HDAC inhibitor,
has been approved by the Food and Drug Administration for
the treatment of refractory cutaneous T-cell lymphoma. This
led to the evaluation of vorinostat and other HDAC inhibitors
in a variety of cancers. Dr. Charles Rudin explained the
rationale for the use of HDAC inhibitors in cancer at this
meeting.
Vorinostat
Dr. Chandra Belani provided an update on the devel-
opment of vorinostat in NSCLC. This agent has demonstrated
modest effects as monotherapy in patients with advanced
NSCLC in a phase II study, but no responses were noted.2
Therefore, a combination strategy involving vorinostat with
carboplatin and paclitaxel was developed by Ramalingam et
al.3 The safety of this regimen was evaluated in a phase I
study, which documented robust responses in patients with
advanced NSCLC. This led to a placebo-controlled random-
ized phase II study of carboplatin and paclitaxel with or
without vorinostat for first-line therapy.4 There was a statis-
tically significant improvement in response rate (34% versus
13%) with the addition of vorinostat and also a trend toward
improved progression-free survival (6 versus 4.1 m) and
median survival (13 versus 9.7 m). Certain toxicities such as
thrombocytopenia, nausea, emesis, diarrhea, and fatigue were
more common with vorinostat and chemotherapy. In contrast
to the encouraging results of this study, a phase II/III study
conducted by Merck noted no improvement in efficacy with
the addition of vorinostat to chemotherapy. The two studies
used a different schedule and also had differences in patient
eligibility criteria. Overall, the issue regarding toxicities as-
sociated with vorinostat that led to the discontinuation of
treatment in a number of patients has to be addressed before
further development of this agent in NSCLC. A follow-up
study to evaluate a shorter schedule of vorinostat (5 days on
and 16 days off) is currently being planned.
Entinostat
Entinostat is an orally administered inhibitor of class I
HDAC. It is given once every other week and has a favorable
tolerability profile. Two different strategies are currently
being pursued with this agent. The synergy between HDAC
inhibitors and epidermal growth factor receptor (EGFR) in-
hibitors5 led to a randomized phase II study of erlotinib given
alone or in combination with entinostat to patients with
recurrent or refractory NSCLC. This trial has completed
accrual, and the results are awaited.
Dr. Rudin described another novel strategy of combin-
ing entinostat with a demethylating agent that demonstrated
synergistic induction of gene expression in preclinical stud-
ies.6 A phase I study with the combination of 5-Azacytidine
and entinostat has been completed and demonstrated good
tolerability. The common toxicities were injection site reac-
tions, nausea, emesis, peripheral edema, and electrolyte ab-
normalities. Most of the toxicities were grade 1 or 2 in
severity. One complete response and one partial response
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were noted in 28 evaluable patients. Eight patients had stable
disease. The responses were slow to occur, which indicates
the need for continuation of the combination for at least a few
cycles to achieve responses. The patient who achieved a
complete response had much higher plasma levels of 5-aza-
cytidine than the others. Analysis of the diagnostic biopsy
revealed multiple methylated loci in this patient. A follow-up
study testing a shorter schedule of 5-azacytidine for 8 days of
each cycle is being planned. Entinostat will be given on days
3 and 10 of each cycle.
Romidepsin
Dr. David Gerber presented an update on romidepsin, a
pan-HDAC inhibitor that has demonstrated activity in lung
cancer cell lines. It enhances erlotinib effect on NSCLC cell
lines in vivo and in vitro.7 Inhibition of mitogen-activated
protein kinase phosphorylation by romidepsin correlates with
increased efficacy of erlotinib. A phase I/II study is currently
ongoing to evaluate the combination of erlotinib and ro-
midepsin in advanced NSCLC. The combination has been
tolerated well without any dose-limiting toxicities to date.
Romidepsin is given on days 1, 8, and 15 of each 28-day
cycle. Erlotinib is given from day 4 onward. Dose escalation
has been completed for the 8 mg/m2 and 10 mg/m2 cohorts.
Preliminary correlative studies have demonstrated a near
fivefold increase in histone acetylation.
In addition to these compounds, other HDAC inhibitors
such as panabinostat and belinostat are also in various stages
of clinical investigation.
Proteasome Inhibitors
Ramalingam et al. summarized the data with proteaso-
mal inhibitors in NSCLC. The ubiquitin-proteasome machin-
ery plays an important role in cellular protein degradation and
thereby regulates key cellular functions.8 Inhibition of the
proteasome with bortezomib is used as a standard treatment
approach for patients with multiple myeloma. Bortezomib is
an irreversible inhibitor of the 26 S ribosomal activity. It has
demonstrated modest single-agent activity in patients with
advanced NSCLC.9 The combination of bortezomib with
standard chemotherapy has not resulted in a major improve-
ment over the efficacy of chemotherapy alone and is unlikely
to be pursued further. A phase II study by Ramalingam et al.
with bortezomib in patients with advanced bronchioloalveo-
lar carcinoma noted a promising disease stabilization of 70%.
In a randomized phase II study by Lynch et al., bortezomib
did not add to the efficacy of erlotinib when given as a
combination. Taken together, it is unlikely that bortezomib
will be developed further in NSCLC. Nevertheless, several
newer proteasome inhibitors offer hope based on their favor-
able pharmacokinetic properties and target selectivity over
that of bortezomib. Carfilzomib, an irreversible proteasome
inhibitor, has demonstrated favorable anticancer effects in
bortezomib-refractory cases of myeloma and is currently in
phase II studies. Other proteasomal inhibitors currently under
development include MLN-9708, CEP-18770, PR-047, and
NPI-0052. It is hoped that these agents will demonstrate
favorable anticancer effects in patients with NSCLC.
Dr. Howard West provided the rationale for the use of
the ubiquitin pathway as a target for cancer therapy. Ubiq-
uitin is a highly conserved regulatory protein that labels
proteins for degradation. It controls stability, function, and
cellular localization of a number of important proteins. A
mutation in CBL, an E3 ubiquitin ligase, has been docu-
mented in NSCLC. CBL interacts with EGFR signaling and
could serve as a therapeutic target for combined inhibition
with EGFR inhibitors. PYR-41, an E1 inhibitor, is currently
under investigation in preclinical studies and several other
selective inhibitors are likely to be developed. This group of
agents is very early in the course of development and is not
currently in clinical investigation.
Heat Shock Protein Inhibitors
Heat shock proteins (HSPs) are among the most highly
expressed proteins and account for 1 to 2% of the total protein
in unstressed cells.10 They play an important chaperone
function and facilitate protein folding and transport. HSPs
serve as client proteins for EGFR, HER2, vascular endothe-
lial growth factor receptor 2, phosphatidylinositol 3-kinase,
Akt, Src, HIF1, p53, and CDKs. Based on these observations,
inhibition of HSP has emerged as a therapeutic strategy
against cancer.
AUY 922
Dr. Greg Riely discussed early data with AUY922, a
HSP 90 inhibitor that has demonstrated anticancer effects in
xenograft models. An ongoing phase I study evaluates a
weekly schedule of AUY 922 with an initial dose of 2 mg/m2.
Sixty patients have been enrolled to date. Adverse events
with AUY-922 included asthenia, nausea, diarrhea, and vom-
iting. Visual symptoms were noted at higher doses (40
mg/m2). The dose-limiting toxicities were fatigue, diarrhea
and atrial fibrillation. Maximum tolerated dose is 70 mg/m2.
Though no objective responses have been noted, dose-depen-
dent induction of HSP 70 has been demonstrated. Phase II
evaluation is currently underway.
STA-9090
Dr. Geoffrey Shapiro discussed the development of
STA-9090, a potent second generation small molecule HSP
90 inhibitor (nongeldanamycin). It degrades oncogenic client
proteins and has deep penetration into hypoxic tumors. Pre-
clinical synergy has been noted with a variety of other
anticancer agents. Phase I evaluation of STA-9090 has been
completed with a 1-hour intravenous infusion given once or
twice weekly. This novel agent depletes mutant EGFR in low
concentrations and has demonstrated activity in EGFR resis-
tant cell lines. It also depletes MET thereby providing another
mechanism to overcome EGFR resistance. A phase II study is
currently underway in patients with advanced NSCLC. Three
cohorts of patients will be enrolled: EGFR mutation with
failure of EGFR TKI, KRAS mutation, and KRAS wild type.
A phase I study of STA-9090 in combination with docetaxel
will soon be initiated.
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IPI-504
Dr. Sequist discussed the promising early data with
IPI-504, a potent and selective inhibitor of HSP90. It has
demonstrated a response rate of 7% when given as mono-
therapy in a cohort of patients with heavily pretreated ad-
vanced NSCLC. This study is built on the observation that
mutated EGFR is a sensitive client protein of HSP90. Both
T790 mutation and MET amplification are susceptible to
HSP90 inhibition, and therefore, an ongoing study is evalu-
ating the role of IPI-504 in patients who failed prior therapy
with an EGFR inhibitor. Two confirmed responses have been
noted among 28 patients with wild-type EGFR, though none
were seen in patients with mutated EGFR. IPI-504 was
tolerated well, and the study is ongoing.
CONCLUSIONS AND FUTURE DIRECTIONS
Lung cancer is a heterogenous disease and is often not
driven by a single molecular pathway. Therefore, therapeutic
approaches that target multiple pathways are necessary for
treatment of NSCLC. HDAC, proteasome, and HSP inhibi-
tors have the ability to target a number of vital targets and,
therefore, represent promising avenues for therapy. Further
characterization of the specific molecular targets, develop-
ment of novel combinations, and evaluation for predictive
biomarkers are important next steps.
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